Study on predictive role of AR and EGFR family genes with response to neoadjuvant chemotherapy in locally advanced breast cancer in Indian women

Medical Oncology

Volumn 29, Issue 2, 2012, Pages 539-546

  Singh, L C ^a   Chakraborty, Anurupa ^a   Mishra, Ashwani K ^a   Devi, Thoudam Regina ^a   Sugandhi, Nidhi ^a   Chintamani, Chintamani ^a   Bhatnagar, Dinesh ^a   Kapur, Sujala ^a   Saxena, Sunita ^a  

^a SAFDARJUNG HOSPITAL   (India)

Author keywords

5 fluorouracil (CAF); Adriamycin; Cyclophosphamide; Gene expression; Locally advanced breast cancer; Neoadjuvant chemotherapy; Non responders; Responders

Indexed keywords

ANDROGEN RECEPTOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; FLUOROURACIL; GROWTH HORMONE RECEPTOR; MULTIDRUG RESISTANCE PROTEIN 1; STEROID RECEPTOR; ABCB1 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; AR PROTEIN, HUMAN; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERBB2 PROTEIN, HUMAN; GLYCOPROTEIN P; MESSENGER RNA;

ADJUVANT THERAPY; ADULT; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; FEMALE; GENE EXPRESSION; GENE FUNCTION; HUMAN; HUMAN TISSUE; MULTIPLE CYCLE TREATMENT; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; TREATMENT RESPONSE; ADJUVANT CHEMOTHERAPY; AGED; BREAST TUMOR; CANCER STAGING; FOLLOW UP; GENETICS; INDIA; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; INDIA; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; P-GLYCOPROTEIN; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; RECEPTORS, ANDROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84866334301     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-011-9952-6     Document Type: Article

References (57)

1. Chopra R. The Indian scene. J Clin Oncol. 2001;19:S106-11.
2. Chintamani SV, Singh JP, Lyall A, Saxena S, Bansal A. Is druginduced toxicity a good predictor of response to neo-adjuvant chemotherapy in patients with breast cancer?-a prospective clinical study. BMC Cancer 2004;4:48.
3. Chintamani SV, Singh JP, Mittal MK, Saxena S, Bansal A, Bhatia A, Kulshreshtha P. Role of p-glycoprotein expression in predicting response to neoadjuvantchemotherapy in breast cancer- a prospective clinical study. World J Surg Oncol. 2005;3:61.
4. Wallner J, Depisch D, Hopfner M, Haider K, Spona J, Ludwig H, Pirker R. MDR1 gene expression and prognostic factors in primary breast carcinomas. Eur J Cancer. 1991;27:1352-5.
5. Dixon AR, Bell J, Ellis IO, Elston CW, Blamey RW. P-glycoprotein expression is locally advanced breast cancer treated by neoadjuvant chemotherapy. Br J Cancer. 1992;66:537-41.
6. De Lena M, Zucali R, Viganotti G, Valagussa P, Bonadonna G. Combination chemotherapy, radiotherapy approach in locally advanced breast cancer. Cancer Chemother Pharmacol. 1978;1: 53-9.
7. Sataloff DM, Mason BA, Prestipino AJ, Seinige UL, Lieber CP, Baloch Z. Pathological response to induction chemotherapy in locally advanced carcinoma of breast, a determinant of out come. J Am Coll Surg. 1995;180:297-306.
8. Seymour L, Bezwoda WR, Dansey RD. p-Glycoprotein immunostaining correlates with ER and with high Ki67 expression but fails to predict anthracycline resistance in patients with advanced breast cancer. Breast Cancer Res Treat. 1995;36:61-9.
9. Charfare H, Limongelli S, Purushotham AD. Neo-adjuvant chemotherapy in breast cancer. Br J Surg. 2005;92:14-23.
10. Mendelsohn J. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clin Cancer Res. 1997;3:2703-7.
11. Sainsbury JRC, Farndon JR, Needham GK, Malcolm AJ, Harris AL. Epidermal growth factor receptor status as predictor of early recurrence and death from breast cancer. Lancet 1987;1398-1402.
12. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire L. Human breast cancer. Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (Washington DC) 1987;235:177-182.
13. Klijn JGM, Berns PMJJ, Schmitz PIM, Foekens JA. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr Rev. 1992;13:3-17.
14. Bhargava R, Gerald WL, Li AR, Pan Q, Lal P, Ladanyi M, et al. EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations. Modern Pathol. 2005;18:1027-33.
15. Re'villion F, Bonneterre J, Peyrat JP. ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer 1998;34: 791-808.
16. Ross JS, Fletcher JA, Linette GP, Stec J, Clark E, Ayers M, et al. The Her-2/neu gene and protein in breast cancer : biomarker and target of therapy. Oncologist. 2003;8:307-25.
17. Tokuda Y, Okumura A, Ohta M, Kubota M, Ohnishi Y, Shmamura K, et al. A humanized Anti-c-erbB-2 monoclonal antibody for the treatment of breast cancer. Breast cancer. 1997;4:269-72.
18. Shak S. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Semin. Oncol. 1999;26:71-77.
19. Burstein HJ, Harris LN, Gelman R, et al. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/ cyclophosphamide for HER2 over-expressing stage II or III breast cancer: a pilot study. J Clin Oncol. 2003;21:46-53.
20. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707-12.
21. Paterson MC, Dietrich KD, Danyluk J, Paterson AH, Lees AW, Jamil N, et al. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer. Cancer Res. 1991;51:556-67.
22. Gullick WJ, Love SB, Wright C, Barnes DM, Gusterson B, Harris AL, et al. c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer. 1991;63:434-8.
23. Andrulis IL, Bull SB, Blackstein ME, Sutherland D, Mak C, Sidlofsky S, Pritzker KP, Hartwick RW, Hanna W, Lickley L, et al. neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group. J Clin Oncol 1998;16:1340-1349.
24. Thor AD, Liu S, Edgerton S, Moore D 2nd, Kasowitz KM, Benz CC, et al. Activation (tyrosine phosphorylation) of ErbB-2 (HER- 2/neu): a study of incidence and correlation with outcome in breast cancer. J Clin Oncol. 2000;18:3230-9.
25. Penuel E, Akita RW, Sliwkowski MX. Identification of a region within the ErbB2/HER2 intracellular domain that is necessary for ligand-independent association. J Biol Chem. 2002;277:28468-73.
26. Gullick WJ. Prevalence of aberrant expression of epidermal growth factor receptor in human cancer cells. Br Med Bull. 1991;47:87-98.
27. deFazio A, Chiew YE, Sini RL, Janes PW, Sutherland RL. Expression of c-erbB receptors, heregulin and oestrogen receptor in human breast cell lines. Int J Cancer. 2000;87:487-98.
28. Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas CF 3rd, Hynes NE. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci USA. 2003;100(15):8933-8.
29. Soreide JA, Lea OA, Varhaug JE, Skarstein A, Kvinnsland S. Androgen receptors in operable breast cancer: relation to other steroid hormone receptors, correlations to prognostic factors and predictive value for effect of adjuvant tamoxifen treatment. Eur J Surg Oncol. 1992;18:112-8.
30. Szelei J, Jimenez J, Sotto AM, Luizzi MF, Sonnenschein C. Androgen induced inhibition of proliferation in human breast cancer MCF7 cells transfected with androgen receptor. Endocrinology. 1997;138:1406-12.
31. Bryan RM, Mercer RJ, Bennett RC, Rennie GC, Lie TH, Morgan FJ. Androgen receptors in breast cancer. Cancer. 1984;54:2436-40.
32. Buchanan G, Birrell SN, Peters AA, Bianco-Miotto T, Ramsay K, Cops EJ, et al. Decreased androgen receptor levels and receptor function in breast cancer contribute to the failure of response to medroxyprogesterone acetate. Cancer Res. 2005;65(18):8487-96.
33. Birrell SN, Roder DM, Horsfall DJ, Bentel JM, Tilley WD. Medroxyprogesterone acetate therapy in advanced breast cancer: the predictive value of androgen receptor expression. J Clin Oncol. 1995;13:1572-7.
34. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta. 1976;455:152-62.
35. Nooter K, Herweijer H. Multidrug resistance (mdr) genes in human cancer. Br J Cancer. 1991;63:663-9.
36. Inaji H, Komoike Y, Motomura K, Kasugai T, Sawai Y, Koizumi M, et al. Breast-conserving treatment after neoadjuvant chemotherapy in large breast cancer. Breast cancer. 2002;9:20-5.
37. Tiezzi DG, Andrade JM, Marana HR, Zola FE, Peria FM. Breast conserving surgery after neoadjuvant therapy for large primary breast cancer. Eur J Surg Oncol. 2008;34:863-7.
38. Zhang F, Yang Y, Smith T, Kau SW, McConathy JM, Esteva FJ, et al. Correlation between HER-2 expression and response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma. Cancer. 2003;97:1758-65.
39. Favret AM, Carlson RW, Goffinet DR, Jeffrey SS, Dirbas FM, Stockdale FE. Locally advanced breast cancer. Is surgery necessary? Breast J. 2001;7:131-7.
40. Davidson K, Cameron DA, Dillon P, Bowman A, Stewart M, Leonard RCF. Locally advanced breast cancer: the outcome of primary polychemotherapy based on infusional 5 fluorouracil. The Breast. 1999;8:110-5.
41. Fukuda M, Yamaguchi S, Ohta Y, Nakayama Y, Ogata H, Shimizu K, et al. Combination therapy for advanced breast cancer: cyclophosphamide, Doxorubicin, UFT, and Tamoxifen. Oncology. 1999;7:77-81.
42. Schneider S, Uchida K, Brabender J, et al. Downregulation of TS, DPD, ERCC1, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer. J Am Coll Surg. 2005;200:336-44.
43. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 1995;19:183-232.
44. Chevillard S, Pouillart P, Beldjord C, Asselain B, Beuzeboc P, Magdelénat H, et al. Sequential assessment of multidrug resistance phenotype and measurement of S-phase fraction as predictive markers of breast cancer response to neoadjuvant chemotherapy. Cancer 1996;77(2):292-300.
45. Liu XE, Sun XD, Wu JM. Effect of NACT on MDR1 and MRP gene expression in primary breast cancer. Chin J Cancer Res. 2004;16(1):51-4.
46. Seymour L, Bezwoda WR, Dansey RD. P-glycoprotein immunostaining correlates with ER and with high Ki67 expression but fails to predict anthracycline resistance in patients with advanced breast cancer. Breast Cancer Res Treat. 1995;36(1):61-9.
47. Parton M, Krajewski S, Smith I, et al. Coordinate expression of apoptosis-associated proteins in human breast cancer before and during chemotherapy. Clin Cancer Res. 2002;8:2100-8.
48. Chang J, Powles TJ, Allred DC, et al. Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Oncol. 1999;17:3058-63.
49. Ellis PA, Smith IE, Detre S, et al. Reduced apoptosis and proliferation and increased Bcl-2 in residual breast cancer following preoperative chemotherapy. Breast Cancer Res Treat. 1998;48:107-16.
50. Chang J, Ormerod M, Powles TJ, Allred DC, Ashley SE, Dowsett M. Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma. Cancer (Phila). 2000;89:2145-52.
51. Borg A, Baldetorp B, Ferno M, Killander D, Olsson H, Sigurdsson H. ErbB2 amplification in breast cancer with a high rate of proliferation. Oncogene. 1991;6:137-43.
52. Marks JR, Humphrey PA, Wu K, Berry D, Bandarenko N, Kerns BJ, et al. Overexpression of p53 and HER-2/neu proteins as prognostic markers in early stage breast cancer. Ann Surg. 1994;219:332-41.
53. Paik S, Bryant J, Tan-Chiu E, Yothers G, Park C, Wickerham DL, et al. HER2 and choice of adjuvant chemotherapy for invasive breast cancer: NSABP B-15. J Natl Cancer Inst (Bethesda). 2000;92:1991-8.
54. Paik S, Bryant J, Park C, Fisher B, Tan-Chiu E, Hyams D, et al. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst (Bethesda). 1998;90:1361-70.
55. Harris L, Tang C, Yang C, Harris A, Lupu R. Induction of chemotherapy sensitivity in MCF-7 breast cancer cells by heregulin. Clin Cancer Res. 1998;4:1005-12.
56. Zhang Y, Wang XW, Jelovac D, et al. The ErbB3-binding protein Ebp1 suppresses androgen receptor-mediated gene transcription and tumorigenesis of prostate cancer cells. Proc Natl Acad Sci USA. 2005;102:9890-5.
57. Mellinghoff IK, Vivanco I, Kwon A, Tran C, Wongvipat J, Sawyers CL. HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell. 2004;6:517-27.